Traitement expérimental de la trypanosomiase africaine par le facteur trypanolytique humain combiné à un nanocorps

Medecine/Sciences

Volumn 22, Issue 11, 2006, Pages 914-916

  Baral, Toya Nath ^a   Magez, Stefan ^a   Stijlemans, Benoît ^a   Conrath, Katja ^a   Vanhollebeke, Benoit ^b   Pays, Etienne ^b   Muyldermans, Serge ^a   Baetselier, Patrick De ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITRYPANOSOMAL AGENT; NANOMATERIAL; PLASMA PROTEIN;

AFRICAN TRYPANOSOMIASIS; ARTICLE; HUMAN;

BLOOD PROTEINS; HUMANS; NANOSTRUCTURES; TRYPANOCIDAL AGENTS; TRYPANOSOMIASIS, AFRICAN;

EID: 39049174717     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/20062211914     Document Type: Article

References (10)

1. Pays E, Vanhamme L, Perez-Morga D. Antigenic variation in Trypanosoma brucei: facts, challenges and mysteries. Curr Opin Microbiol 2004; 7 : 369-74.
2. Legros D, Ollivier G, Gastellu-Etchegorry M, et al. Treatment of human African trypanosomiasis : present situation and needs for research and development.Lancet Infect Dis 2002; 2 : 437-40.
3. Xong HV, Vanhamme L, Chamekh M, et al. A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense. Cell 1998; 95 : 839-46.
4. Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature 2003; 422 : 83-7.
5. Pays E, Vanhollebeke B, Vanhamme L, et al. The trypanolytic factor of human serum. Nat Rev Microbiol 2006; 4:477-86.
6. Muyldermans S. Single domain camel antibodies: current status. J Biotechnol 2001; 74 : 277-302.
7. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363 : 446-8.
8. Stijlemans B, Conrath K, Cortez-Retamozo V, et al. Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem 2004; 279 : 1256-61.
9. Baral TN, Magez S, Stijlemans B, et al. Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat Med 2006; 12:580-4.
10. Conrath K, Vincke C, Stijlemans B, et al. Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH. J Mol Biol 2005; 350 : 1 12-25.